LOGIN  |  REGISTER
Viking Therapeutics
Chimerix

Nyxoah: Information on the total number of voting rights and shares

November 27, 2024 | Last Trade: US$6.76 0.37 5.79
  • Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), November 27, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  • Share capital: EUR 6,429,682.56
  • Total number of securities carrying voting rights: 37,427,265 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,427,265 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued: 2,296,194 (all granted subscription rights; this number excludes 346,431 subscription rights that were issued but not yet granted)

Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page